10
Participants
Start Date
May 23, 2018
Primary Completion Date
September 30, 2019
Study Completion Date
September 30, 2019
Blinatumomab
Blinatumomab is administered as a continuous IV infusion.
Research Site, Lausanne
Research Site, St Leonards
Research Site, Westmead
Research Site, Leuven
Research Site, Bern
Research Site, Clayton
Research Site, Geelong
Research Site, Liège
Research Site, Charleroi
Research Site, Bellinzona
Research Site, Zurich
Research Site, Torino
Research Site, Athens
Research Site, Athens
Research Site, Marseille
Research Site, Milan
Research Site, Bergamo
Research Site, Brescia
Research Site, Atlanta
Research Site, Pessac
Research Site, Montpellier
Research Site, Cleveland
Research Site, Florence
Research Site, Thessaloniki
Research Site, Lille
Research Site, Maywood
Research Site, Pierre-Bénite
Research Site, Dallas
Research Site, Paris
Research Site, Rouen
Research Site, Palermo
Research Site, Créteil
Lead Sponsor
Amgen
INDUSTRY